Environmental

Insmed’s R&D intensity is very high at 75.7% of revenue, which supports a science-led footprint but also concentrates resource use versus larger diversified peers.

Low debt-to-equity of 0.05 and net debt-to-EBITDA of 0.66 reduce balance-sheet pressure, which can support longer-horizon investment in environmental controls versus leveraged peers.

The company’s asset-light, research-driven model likely limits manufacturing emissions exposure relative to peers with large internal production networks, although this advantage is not directly disclosed in the provided metrics.

No direct environmental controversy or compliance issue is indicated in the supplied data, so the main ESG relevance is operational intensity rather than peer-leading environmental stewardship.

Social

High R&D spend at 75.7% of revenue indicates sustained investment in therapies, which can strengthen patient-value creation relative to peers with lower innovation intensity.

Stock-based compensation at 10.4% of revenue suggests meaningful employee alignment, but it also implies dilution pressure that is more visible than at peers with tighter pay structures.

A gross margin of 83.3% supports continued funding for clinical development and patient programs, which can improve social resilience versus peers with weaker operating buffers.

No material labor, product-safety, or access-to-medicine controversy is evident in the provided data, leaving Insmed’s social profile stronger than average but not clearly leading.

Governance

Very low leverage, with debt-to-equity at 0.05, reduces creditor pressure and can improve governance flexibility versus more highly levered peers.

Net debt-to-EBITDA of 0.66 indicates conservative financing, which lowers refinancing risk and supports board discretion relative to peers with tighter capital structures.

Stock-based compensation at 10.4% of revenue is a governance watchpoint, but it remains manageable and does not by itself indicate weaker oversight than peers.

The absence of disclosed governance controversies in the supplied metrics supports a solid, though not exceptional, governance position relative to peers.

Overall Score

Insmed’s ESG positioning is stronger than peers overall because its conservative leverage and research-led model support resilience, while no material controversy is evident in the provided data.

Score Driver: Conservative Balance-Sheet Structure Relative To Peers